Dexamethasone in the maintenance phase of acute lymphoblastic leukaemia treatment: Is the risk of lethal infections too high?
Esther M. te Poele(University Medical Center Groningen), Willem A. Kamps(Pediatric Oncology Group), Auke Beishuizen, Eveline S.J.M. de Bont(Hôpital Saint-Michel), Ilse J.M. Nijhuis(University Medical Center Groningen), Tom Révész, H. Marike Boezen(University Medical Center Groningen), Jos P.M. Bökkerink(Radboud University Nijmegen), Claudi S. M. Oude Nijhuis(University Medical Center Groningen)
Cited by 35
Related Papers
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
|The Lancet|1998|964
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
|The Lancet Oncology|2009|932
Evidence Based Selection of Housekeeping Genes
|PLoS ONE|2007|772
Outcome of Treatment in Children with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2000|599
Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders
|The American Journal of Human Genetics|2018|453